![Robert Levin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 3 M $ al 31/07/2026
Robert S.
Levin worked as a Director at Venturis Therapeutics, Inc.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
Dyadic International, Inc.
 Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products 9 % | 24/07/2026 | 3.280.272 ( 9 % ) | 3 M $ | 31/07/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Researches therapeutic regimens to treat patients with coronary artery disease | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 1 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Researches therapeutic regimens to treat patients with coronary artery disease | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
